Loading data for INDV — first visit, this takes a few seconds.
Indivior Pharmaceuticals, Inc.
34.47 -0.02 (-0.06%)
- Capitalización de mercado
- $4.07B
- Volumen
- 1.72M
- Próxima fecha de resultados
- Nov 5, 2026
Indivior Pharmaceuticals, Inc. (INDV): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | $343.0M | n/a | +13.58% |
| EPS | $1,15 | +$0,23 | +125.49% |
Métricas
- Precio de compra
- 34.74
- Ingresos (TTM)
- 1.33B
- Beneficio neto (TTM)
- 356M
- 1.11
- 2.79
- 12.35
- 7.06
- P/B (TTM)
- -19.55
- P/S (TTM)
- 3.06
- Fecha de resultados
- Nov 5, 2026
- Precio de venta
- 34.74
- Volumen
- 1,719,775
- Volumen medio (20D)
- 2,046,680
- Abierto
- 34.74
- Anterior Cerrar
- 34.49
- Rango del día
- 34.15 - 35.01
- Rango de 52 semanas
- 22.22 - 42.81
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- Jun 16, 2016
Acerca de Indivior Pharmaceuticals, Inc.
Ver perfil →Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Industria Drug Manufacturers - Specialty & Generic
Sector Healthcare
IPO Fecha Dec 29, 2014
Empleados 827
Bolsa de Valores NasdaqGS
Símbolo bursátil INDV
Sitio web https://www.indivior.com